 Connection
Kurt Stenmark to Vasodilator Agents
This is a "connection" page, showing publications Kurt Stenmark has written about Vasodilator Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.622 |
|
|
|
-
Zhang H, D'Alessandro A, Li M, Reisz JA, Riddle S, Muralidhar A, Bull T, Zhao L, Gerasimovskaya E, Stenmark KR. Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension. Vascul Pharmacol. 2023 04; 149:107157.
Score: 0.186
-
Keshavarz A, Alobaida A, McMurtry IF, Nozik-Grayck E, Stenmark KR, Ahsan F. CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil. Mol Pharm. 2019 08 05; 16(8):3414-3429.
Score: 0.144
-
Rashid J, Patel B, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). J Control Release. 2017 03 28; 250:96-106.
Score: 0.122
-
Li M, Stenmark KR, Shandas R, Tan W. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. J Vasc Res. 2009; 46(6):561-71.
Score: 0.072
-
Gupta N, Rashid J, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency. Mol Pharm. 2017 03 06; 14(3):830-841.
Score: 0.031
-
Morin FC, Stenmark KR. Persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med. 1995 Jun; 151(6):2010-32.
Score: 0.027
-
Yeager ME, Colvin KL, Everett AD, Stenmark KR, Ivy DD. Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl. 2012 Jun; 6(5-6):257-67.
Score: 0.022
-
Takeda K, Okamoto M, de Langhe S, Dill E, Armstrong M, Reisdorf N, Irwin D, Koster M, Wilder J, Stenmark KR, West J, Klemm D, Gelfand EW, Nozik-Grayck E, Majka SM. Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. Anat Rec (Hoboken). 2009 Jul; 292(7):1045-61.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|